It’s a very different world now in cancer,” said longtime patient advocate Ginny Mason. “Now you need to understand the ...

Researchers at Fred Hutch Cancer Center invented a new screening method called ReLiC that uses CRISPR-Cas9 to test all the ...

A study published in Nature shows that certain autoantibodies may influence how cancer patients respond to immunotherapy. Autoantibodies are proteins produced by the immune system and have typically ...

Ten Washington state health organizations recently received grants of up to $15,000 from Fred Hutch Cancer Center’s Community ...

In 2024, Obliteride raised more than $9 million for research at Fred Hutch, contributing to more than $58 million raised since 2013. These funds have fueled urgently needed advances in cancer ...

At first glance, art and science might seem like opposite worlds — one driven by imagination and emotion, the other by data ...

Dr. Folashade Otegbeye, facility director of the Therapeutic Products Program at Fred Hutch, works to rapidly translate what researchers are doing in the lab to the bedside. She is the new holder of ...

Going back to school is different for children with cancer Many children look forward to returning to school in the fall, even if it’s only to see their friends. Others might suffer from anxiety. But ...

During his 36-year career at Fred Hutch Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that causes AIDS. He co-founded the field of paleovirology and ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients have been told that multiple myeloma is treatable but not curable. Yet data ...

In just 50 years, Fred Hutch grew from a regional cancer center into a world-class biomedical research and clinical care institution known for its expertise in molecular biology, tumor virology and ...